Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
US Army
Queensland Health
UBS
Baxter
Colorcon
Teva
McKesson
Citi
Dow

Generated: January 19, 2018

DrugPatentWatch Database Preview

Takeda Pharms Usa Company Profile

« Back to Dashboard

What is the competitive landscape for TAKEDA PHARMS USA, and when can generic versions of TAKEDA PHARMS USA drugs launch?

TAKEDA PHARMS USA has seventeen approved drugs.

There are eighty-two US patents protecting TAKEDA PHARMS USA drugs and there have been two Paragraph IV challenges on TAKEDA PHARMS USA drugs in the past three years.

There are one thousand and sixty-nine patent family members on TAKEDA PHARMS USA drugs in fifty-nine countries and one hundred and twenty-nine supplementary protection certificates in fifteen countries.

Summary for Takeda Pharms Usa
International Patents:1069
US Patents:82
Tradenames:17
Ingredients:14
NDAs:17

Drugs and US Patents for Takeda Pharms Usa

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-004 Mar 27, 2012 DISCN No No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-001 Mar 27, 2012 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Takeda Pharms Usa DEXILANT dexlansoprazole CAPSULE, DELAYED RELEASE;ORAL 022287-002 Jan 30, 2009 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Takeda Pharms Usa OSENI alogliptin benzoate; pioglitazone hydrochloride TABLET;ORAL 022426-006 Jan 25, 2013 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Takeda Pharms Usa OSENI alogliptin benzoate; pioglitazone hydrochloride TABLET;ORAL 022426-003 Jan 25, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Takeda Pharms Usa DEXILANT dexlansoprazole CAPSULE, DELAYED RELEASE;ORAL 022287-002 Jan 30, 2009 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Takeda Pharms Usa ULORIC febuxostat TABLET;ORAL 021856-002 Feb 13, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Takeda Pharms Usa DEXILANT dexlansoprazole CAPSULE, DELAYED RELEASE;ORAL 022287-002 Jan 30, 2009 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Takeda Pharms Usa OSENI alogliptin benzoate; pioglitazone hydrochloride TABLET;ORAL 022426-002 Jan 25, 2013 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Takeda Pharms Usa OSENI alogliptin benzoate; pioglitazone hydrochloride TABLET;ORAL 022426-002 Jan 25, 2013 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Takeda Pharms Usa

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Takeda Pharms Usa PREVACID lansoprazole TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL 021428-002 Aug 30, 2002 ➤ Subscribe ➤ Subscribe
Takeda Pharms Usa ACTOS pioglitazone hydrochloride TABLET;ORAL 021073-003 Jul 15, 1999 ➤ Subscribe ➤ Subscribe
Takeda Pharms Usa PREVACID lansoprazole TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL 021428-001 Aug 30, 2002 ➤ Subscribe ➤ Subscribe
Takeda Pharms Usa OSENI alogliptin benzoate; pioglitazone hydrochloride TABLET;ORAL 022426-001 Jan 25, 2013 ➤ Subscribe ➤ Subscribe
Takeda Pharms Usa PREVACID lansoprazole TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL 021428-001 Aug 30, 2002 ➤ Subscribe ➤ Subscribe
Takeda Pharms Usa OSENI alogliptin benzoate; pioglitazone hydrochloride TABLET;ORAL 022426-003 Jan 25, 2013 ➤ Subscribe ➤ Subscribe
Takeda Pharms Usa NESINA alogliptin benzoate TABLET;ORAL 022271-003 Jan 25, 2013 ➤ Subscribe ➤ Subscribe
Takeda Pharms Usa OSENI alogliptin benzoate; pioglitazone hydrochloride TABLET;ORAL 022426-004 Jan 25, 2013 ➤ Subscribe ➤ Subscribe
Takeda Pharms Usa OSENI alogliptin benzoate; pioglitazone hydrochloride TABLET;ORAL 022426-006 Jan 25, 2013 ➤ Subscribe ➤ Subscribe
Takeda Pharms Usa DUETACT glimepiride; pioglitazone hydrochloride TABLET;ORAL 021925-001 Jul 28, 2006 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for TAKEDA PHARMS USA drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 6.25 mg, 12.5 mg and 25 mg ➤ Subscribe 1/25/2017
➤ Subscribe Tablets 12.5 mg/500 mg and 12.5 mg/1000 mg ➤ Subscribe 1/25/2017
➤ Subscribe Tablets 40 mg and 80 mg ➤ Subscribe 2/13/2013
➤ Subscribe Tablets 0.6 mg ➤ Subscribe 12/23/2011
➤ Subscribe Extended-release Tablets 15 mg/1000 mg and 30 mg/1000 mg ➤ Subscribe 9/23/2011
➤ Subscribe Delayed-release Capsule 30 mg ➤ Subscribe 11/30/2010
➤ Subscribe Capsule 60 mg ➤ Subscribe 8/25/2010
➤ Subscribe Tablets 30 mg/2 mg and 30 mg/4 mg ➤ Subscribe 12/22/2009
➤ Subscribe Tablets 8 mg ➤ Subscribe 7/22/2009
➤ Subscribe Tablets 15 mg/500 mg and 15 mg/850 mg ➤ Subscribe 3/6/2008
➤ Subscribe Delayed-release Orally Disinte 15 mg and 30 mg ➤ Subscribe 12/27/2006
➤ Subscribe Delayed-release Pellets/Capsul 15 mg and 30 mg ➤ Subscribe 12/5/2005

Non-Orange Book US Patents for Takeda Pharms Usa

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,445,541 Methods for concomitant administration of colchicine and a second active agent ➤ Subscribe
9,125,908 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT.sub.3 and 5-HT.sub.1A activity for the treatment of cognitive impairment ➤ Subscribe
7,855,175 Peptides that bind to the erythropoietin receptor ➤ Subscribe
6,599,923 Pharmaceutical composition ➤ Subscribe
9,095,588 Process for preparing 1-[2-(2,4-dimethylphenysulfanyl)-pheny]piperazine or pharmaceutically acceptable salt thereof ➤ Subscribe
6,103,742 Pharmaceutical composition ➤ Subscribe
6,166,042 Pharmaceutical composition ➤ Subscribe
6,211,206 Pharmaceutical composition ➤ Subscribe
6,218,429 Tricyclic compounds, their production and use ➤ Subscribe
9,125,910 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT.sub.3 and 5-HT.sub.1A activity for the treatment of cognitive impairment ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Takeda Pharms Usa Drugs

Supplementary Protection Certificates for Takeda Pharms Usa Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2014 00064 Denmark ➤ Subscribe PRODUCT NAME: VILDAGLIPTIN; REG. NO/DATE: EU/1/07/414/001-017 20070926
2014011 Lithuania ➤ Subscribe PRODUCT NAME: ALOGLIPTINUM; REGISTRATION NO/DATE: EU/1/13/844 20130919
C015/2010 Ireland ➤ Subscribe SPC015/2010: 20101001, EXPIRES: 20230420
00357 Netherlands ➤ Subscribe PRODUCT NAME: SITAGLIPTINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVA ARDBAAR ZOUT, IN HET BIJZONDER HET MONOFOSFAAT, EN METFORMINE DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/08/455/001-014 20080716
C0022 France ➤ Subscribe PRODUCT NAME: FEBUXOSTAT; REGISTRATION NO/DATE: EU/1/08/447/001-004 20080421
2014026 Lithuania ➤ Subscribe PRODUCT NAME: DAPAGLIFOZINUM + METFORMINUM; REGISTRATION NO/DATE: EU/1/13/900 20140116
1174135/01 Switzerland ➤ Subscribe FORMER REPRESENTATIVE: BOHEST AG, CH
8 Finland ➤ Subscribe
C0006 France ➤ Subscribe PRODUCT NAME: PIOGLITAZONE/METFORMINE ET LEURS SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: EU/1/06/354/001 DU 20060728; REGISTRATION NO/DATE AT EEC: EU/1/06/354/001 DU 20060728
2014011,C1586571 Lithuania ➤ Subscribe PRODUCT NAME: ALOGLIPTINAS; REGISTRATION NO/DATE: EU/1/13/844 20130919
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
US Department of Justice
AstraZeneca
Covington
Fuji
Argus Health
UBS
Farmers Insurance
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot